Cargando…

Future perspectives in pulmonary arterial hypertension

While there have been advances in the field of pulmonary arterial hypertension (PAH), disease management remains suboptimal for many patients. The development of novel treatments and strategies can provide opportunities to target other mechanisms that play a role in the complex pathobiology of PAH o...

Descripción completa

Detalles Bibliográficos
Autores principales:	Simonneau, Gérald, Hoeper, Marius M., McLaughlin, Vallerie, Rubin, Lewis, Galiè, Nazzareno
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	European Respiratory Society 2016
Materias:	Mini-Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9487553/ https://www.ncbi.nlm.nih.gov/pubmed/27903660 http://dx.doi.org/10.1183/16000617.0084-2016

Ejemplares similares

New horizons in pulmonary arterial hypertension management
por: McLaughlin, Vallerie, et al.
Publicado: (2014)

A paradigm shift in pulmonary arterial hypertension management
por: Rubin, Lewis J., et al.
Publicado: (2013)

Improving patient outcomes in pulmonary hypertension
por: Galiè, Nazzareno, et al.
Publicado: (2015)

An overview of the 6th World Symposium on Pulmonary Hypertension
por: Galiè, Nazzareno, et al.
Publicado: (2019)

Selexipag for the treatment of connective tissue disease-associated pulmonary arterial hypertension
por: Gaine, Sean, et al.
Publicado: (2017)

Association of N-Terminal Pro Brain Natriuretic Peptide and Long-Term Outcome in Patients With Pulmonary Arterial Hypertension: Insights From the Phase III GRIPHON Study
por: Chin, Kelly M., et al.
Publicado: (2019)

Targeting the Prostacyclin Pathway with Selexipag in Patients with Pulmonary Arterial Hypertension Receiving Double Combination Therapy: Insights from the Randomized Controlled GRIPHON Study
por: Coghlan, J. Gerry, et al.
Publicado: (2018)

Selexipag treatment for pulmonary arterial hypertension associated with congenital heart disease after defect correction: insights from the randomised controlled GRIPHON study
por: Beghetti, Maurice, et al.
Publicado: (2019)

Early selexipag initiation and long-term outcomes: insights from randomised controlled trials in pulmonary arterial hypertension
por: Coghlan, J. Gerry, et al.
Publicado: (2023)

The impact of comorbidities on selexipag treatment effect in patients with pulmonary arterial hypertension: insights from the GRIPHON study
por: Rosenkranz, Stephan, et al.
Publicado: (2021)

Initial combination therapy with ambrisentan and tadalafil in connective tissue disease-associated pulmonary arterial hypertension (CTD-PAH): subgroup analysis from the AMBITION trial
por: Coghlan, John Gerry, et al.
Publicado: (2017)

Long-Term Survival, Safety and Tolerability with Selexipag in Patients with Pulmonary Arterial Hypertension: Results from GRIPHON and its Open-Label Extension
por: Galiè, Nazzareno, et al.
Publicado: (2021)

Pulmonary arterial hypertension: tailoring treatment to risk in the current era
por: Gaine, Sean, et al.
Publicado: (2017)

Risk stratification and medical therapy of pulmonary arterial hypertension
por: Galiè, Nazzareno, et al.
Publicado: (2019)

The revised definition of pulmonary hypertension: exploring the impact on patient management
por: Simonneau, Gérald, et al.
Publicado: (2019)

Elevated Pulmonary Pressure Noted on Echocardiogram: A Simplified Approach to Next Steps
por: Kanwar, Manreet K., et al.
Publicado: (2021)

New horizons in pulmonary arterial hypertension therapies
por: Galiè, Nazzareno, et al.
Publicado: (2013)

Pulmonary Arterial Hypertension: Combination Therapy in Practice
por: Burks, Marsha, et al.
Publicado: (2018)

Upfront Combination Therapy for Pulmonary Arterial Hypertension: Time to Be More Ambitious than AMBITION
por: Cascino, Thomas M., et al.
Publicado: (2021)

Beyond the World Symposium on Pulmonary Hypertension: practical management of pulmonary arterial hypertension and evolving concepts
por: Vachiéry, Jean-Luc, et al.
Publicado: (2019)

Incident and prevalent cohorts with pulmonary arterial hypertension: insight from SERAPHIN
por: Simonneau, Gérald, et al.
Publicado: (2015)

Long-Term Safety, Tolerability and Survival in Patients with Pulmonary Arterial Hypertension Treated with Macitentan: Results from the SERAPHIN Open-Label Extension
por: Souza, Rogério, et al.
Publicado: (2022)

Acute Right Ventricular Failure in the Setting of Acute Pulmonary Embolism or Chronic Pulmonary Hypertension: A Detailed Review of the Pathophysiology, Diagnosis, and Management
por: Matthews, Jennifer Cowger, et al.
Publicado: (2008)

GPs Meet Rare Lung Disorders Task Force factsheet: pulmonary arterial hypertension
por: Galiè, Nazzareno, et al.
Publicado: (2015)

Pulmonary arterial hypertension: from the kingdom of the near-dead to multiple clinical trial meta-analyses
por: Galiè, Nazzareno, et al.
Publicado: (2010)

Clinical outcomes stratified by baseline functional class after initial combination therapy for pulmonary arterial hypertension
por: White, R. James, et al.
Publicado: (2019)

Association between six-minute walk distance and long-term outcomes in patients with pulmonary arterial hypertension: Data from the randomized SERAPHIN trial
por: Souza, Rogério, et al.
Publicado: (2018)

Pathogenesis of pulmonary arterial hypertension: lessons from cancer
por: Guignabert, Christophe, et al.
Publicado: (2013)

The changing landscape of pulmonary arterial hypertension and implications for patient care
por: Hoeper, Marius M., et al.
Publicado: (2014)

Advanced pulmonary arterial hypertension: mechanical support and lung transplantation
por: Bartolome, Sonja, et al.
Publicado: (2017)

The need to move from 6-minute walk distance to outcome trials in pulmonary arterial hypertension
por: Gaine, Sean, et al.
Publicado: (2013)

Sotatercept for the treatment of pulmonary arterial hypertension: PULSAR open-label extension
por: Humbert, Marc, et al.
Publicado: (2023)

SERAPHIN haemodynamic substudy: the effect of the dual endothelin receptor antagonist macitentan on haemodynamic parameters and NT-proBNP levels and their association with disease progression in patients with pulmonary arterial hypertension
por: Galiè, Nazzareno, et al.
Publicado: (2017)

Increased CD39 Nucleotidase Activity on Microparticles from Patients with Idiopathic Pulmonary Arterial Hypertension
por: Visovatti, Scott H., et al.
Publicado: (2012)

Riociguat in patients with chronic thromboembolic pulmonary hypertension: results from an early access study
por: McLaughlin, Vallerie V., et al.
Publicado: (2017)

Pulmonary arterial hypertension
por: Montani, David, et al.
Publicado: (2013)

Switching to riociguat: a potential treatment strategy for the management of CTEPH and PAH
por: Benza, Raymond L., et al.
Publicado: (2020)

A meta-analysis of randomized controlled trials in pulmonary arterial hypertension
por: Galiè, Nazzareno, et al.
Publicado: (2009)

Pharmacological therapy for patients with chronic thromboembolic pulmonary hypertension
por: Hoeper, Marius M.
Publicado: (2015)

Pulmonary Hypertension: Types and Treatments
por: Rose-Jones, Lisa J, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_1of5mqh0qgom9nchme32takv4o